Evercore ISI Reiterates Buy Rating on PROCEPT BioRobotics
Evercore ISI Group reiterated its 'buy' rating for PROCEPT BioRobotics with a price target of $30, a 39.60% upside from the current price.
Key Points
- Evercore ISI Group reiterated its 'buy' rating for PROCEPT BioRobotics (PRCT) with a $30 price target on June 24, 2026.
- Evercore ISI Group's $30 price target implies 39.60% upside from PROCEPT BioRobotics Corporation's ($PRCT) current $21.49 share price.
- Shares of NasdaqGM:PRCT traded near $20.6 on Wednesday, with a market cap of about $1.2 billion and a 52-week range of $19.35 to $62.17.
- Recent insider buying activity included several executives purchasing shares on June 9, 2026, as detailed in the latest filings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Evercore ISI Group has reiterated its 'buy' rating on PROCEPT BioRobotics Corporation (NasdaqGM:PRCT) with a price target of $30. The announcement was made on June 24, 2026, by analyst Vijay Kumar.
Evercore ISI Group vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
PROCEPT BioRobotics Corporation Stock Up 3.2%
Shares of PROCEPT BioRobotics traded around $20.6 on Wednesday. The company, which specializes in medical devices for urology, has a market capitalization of approximately $1.2 billion. Its stock has seen a 52-week low of $19.35 and a high of $62.17. The firm has a forward P/E ratio of -24.3 and a beta of 0.847. Key financial health indicators include a current ratio of 6.73 and a quick ratio of 5.38.
$PRCT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
PROCEPT BioRobotics reported revenue of $322 million with a growth rate of 20.2%. Despite these positive revenue figures, the company is not yet profitable, posting a net margin of -31.8% and a return on equity of -27.8%. The next earnings report is expected on August 10, 2026.
Insider Buying and Selling at PROCEPT BioRobotics Corporation
In recent insider activity, several executives, including Desai Antal Rohit, Amy Dodrill, and Thomas Prescott, purchased shares on June 9, 2026. Each insider acquired shares at no disclosed cost, indicating potential confidence in the company's future.
Analysts Set New Price Targets
On June 24, 2026, Evercore ISI Group reiterated its 'buy' rating for PROCEPT BioRobotics with a $30 price target. Earlier, on June 11, 2026, Leerink Partners downgraded the stock to 'hold' with a $29 target. Piper Sandler also reiterated a 'buy' rating with a $35 target on April 30, 2026. The consensus among nine analysts is a 'buy' rating with an average price target of $30.22.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, headquartered in San Jose, California, is a healthcare company focused on developing surgical robotics solutions for urology. Its flagship product, the AquaBeam Robotic System, is used for minimally invasive urologic surgery, particularly for treating benign prostatic hyperplasia. The company, led by CEO Larry L. Wood, employs 888 people and continues to innovate in the medical devices industry.
Bottom Line
Evercore ISI Group's reaffirmation of its 'buy' rating for PROCEPT BioRobotics underscores continued confidence in the company's prospects. Investors track these analyst ratings closely, although it's important to remember that such recommendations are based on past data and market conditions. As always, 13F filings and analyst reports provide a snapshot of institutional sentiment and are not indicative of future performance.
Get PROCEPT BioRobotics Corporation alerts
New 13F filings, insider trades, and analyst moves on $PRCT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.